TP-317 represents a novel approach to treating inflammatory bowel disease (IBD) based on activating intrinsic resolution and repair pathways without compromising immune function BRANFORD, CT – (May 18, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company with platform technology developing a new class of Resolvin-based therapies for gastrointestinal inflammatory diseases, today announced preclinical data […]
BRANFORD, CT – (May 6, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company focused on novel gastrointestinal therapies that promote mucosal healing, announced today that Ron Lennox, D.Phil., has joined its Board of Directors. Dr. Lennox, a prolific biotechnology entrepreneur and investor over the last 30 years, will work with Thetis senior management as it […]
Professor Serhan to guide advancement of resolvin-based therapies into clinical investigation for treatment of inflammatory diseases BRANFORD, CT – (February 19, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing Resolvin-based therapies to treat inflammatory diseases, announced today that Professor Charles N. Serhan has joined its Scientific Advisory Board.
Novel Resolvin-based drug candidate offers potential first-in-class, oral, small molecule therapy for IBD BRANFORD, CT – (November 13, 2018) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing novel Resolvin-based therapies to treat inflammatory diseases, was selected by the Crohn’s & Colitis Foundation to present on TP-317, its lead drug candidate for inflammatory bowel disease […]
BRANFORD, CT – (July 17, 2018) – Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal diseases, announced today that the USPTO has granted patent US 9,999,626 providing composition of matter protection for its IBD development candidates. The allowed claims include pharmaceutical compositions that are mineral amino-acid based derivatives of fatty acids with 16 […]